詳細
We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
特異性
Clone LN53 is a ZooMAb® rat recombinant monoclonal antibody that specifically detects Human herpesvirus-8/Kaposi′s sarcoma-associated herpesvirus (HHV-8/KSHV) and macaque retroperitoneal fibromatosis herpesvirus (RFHV). It targets an epitope within the C-terminal domain.
免疫原
Affinity-purified GST fusions of C-terminal fragments of HHV-8 LNA-1 (See: Kellam, P., et al. (1999). J. Virol. 73(6); 5149-5155).
アプリケーション
Quality Control Testing
Evaluated by Western Blotting in Body Cavity Based Lymphoma-1 (BCBL-1) cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected HHV-8 LNA-1 in Body Cavity Based Lymphoma-1 (BCBL-1) cell lysate.
Tested Applications
Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected HHV-8 LNA-1 in BCBL1 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected HHV-8 LNA-1 in Human Kaposi′s sarcoma tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
ターゲットの説明
Human herpesvirus-8 (also known as Kaposi′s sarcoma-associated herpesvirus, HHV-8, KSHV) is etiologically associated with all forms of Kaposi sarcoma (KS) including classic, endemic, transplant-related, and AIDS-related, as well as rare neoplastic disorders. It is a double stranded DNA virus with a large genome that encodes for over 87 open reading frames (ORFs) including genes necessary for capsid, tegument, envelope, DNA replication and regulatory proteins. HHV-8 undergoes a bi-phasic lifecycle and can persist indefinitely in the infected host in a latent form during which time only a small fraction of regulatory viral proteins is expressed. The most prominent protein expressed in latently infected cells is the ORF73 gene product known as the latency-associated nuclear antigen (LANA) that functions to ensure the maintenance of the viral genome by tethering the viral episomal DNA to host cell chromosomes. The ORF59 (also known as PF-8), a phosphoprotein, is reported to be a processivity factor for HHV-8 DNA polymerase (Pol-8). It interacts with and stimulates Pol-8 DNA synthesis activity. It is an early-late gene product localized to HHV-8-infected cell nuclei. PF-8 interacts with HHV-8 DNA polymerase (Pol-8) and stimulates Pol-8 DNA synthesis activity. Amino acid residues 10-27 and 279-301 are reported to be critical for the processivity function of PF-8. Residues 10 to 27 are essential for its interaction with Pol-8 and 279-301 are required for its binding to dsDNA. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Strahan, RC., et al. (2017). PLoS Pathog 13(7); e1006482; Chan, SR., and Chandran, B (2000). J. Virol. 74(23); 10920-10929; Kellam, P., et al. (1999). J. Virol. 73(6); 5149-5155; Chan, SR., et al. (1998). 240: 118-126).
物理的形状
Purified recombinant rat monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
再構成
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
保管および安定性
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
法的情報
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.